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SUMMARY 
The anesthetic-sedative barbiturate pentobarbital (PB) and the anticonvulsant 
barbiturate phenobarbital (PhB) were applied to mammalian spinal cord neurons in 
primary dissociated cell culture to assess their effects on: (1) postsynaptic GABA- 
responses; (2) paroxysmal activity produced by the convulsant bicuculline; (3) resting 
membrane properties; and (4) spontaneous neuronal activity. The results demonstra- 
ted that: (I) anticonvulsant actions occurred at barbiturate concentrations which 
augmented GABA-responses; (2) anesthetic actions occurred at barbiturate concen- 
trations which produced direct increases in chloride conductance; (3) both anti- 
convulsant and anesthetic actions occurred at clinically relevant concentrations; and 
(4) concentrations of PhB, but not PB, which produced GABA-augmentation and 
direct conductance changes were widely separated. These findings support the hypo- 
theses that augmentation of  GABA-mediated inhibition and possibly reduction of 
glutamate (GLU)-mediated excitation form the basis at least in part for barbiturate 
anticonvulsant action and that addition of direct increases in chloride conductance to 
augmentation of  GABA-mediated inhibition and reduction of GLU-mediated excitat- 
ion may partially underlie anesthetic-sedative barbiturate action. 
INTRODUCTION 
The barbiturates phenobarbital (PhB) and pentobarbital (PB) are used clinically 
as anticonvulsants, sedatives and anesthetics. While PB is an effective anticonvulsant, 
it is not used as such due to its undesirable sedative properties. In contrast, PhB can be 
administered to ambulatory patients at doses which provide substantial anticonvul- 
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sant action without producing sedation 2s. While barbiturates have been demonstrated 
to have multiple actions on neuronal membrane properties2,12,14,17,27 and to have pre- 
6,8,9,1s,29,a0 and postsynaptic18,14,17, ~4,29,3° actions on synaptic transmission, it re- 
mains uncertain as to which of these actions are responsible for their clinical effects 
and why barbiturates have variable efficacy as anticonvulsants, sedatives and anesthe- 
tics. It has been suggested recently that while anticonvulsant and anesthetic barbitu- 
rates have similar pharmacological and electrophysiological actions, the dose-depen- 
dencies of these actions are substantially different 12,14. Using iontophoresis of barbitu- 
rates and amino acids onto mouse spinal cord neurons in primary dissociated cell 
culture, it was demonstrated that anticonvulsant and anesthetic barbiturates augmen- 
ted GABA-mediated postsynaptic inhibition and antagonized glutamate (GLU)- 
mediated postsynaptic excitation over similar iontophoretic current ranges, but that 
anesthetic barbiturates directly increased postsynaptic chloride conductance at much 
lower iontophoretic charges than anticonvulsant barbiturates. It was then suggested 
that anticonvulsant actions of barbiturates might be due to augmentation of GABA- 
mediated inhibition and possibly antagonism of GLU-mediated excitation, and that 
the anesthetic-sedative actions of barbiturates might be the result of addition of direct 
chloride-mediated increases in membrane conductance to the GABA-response aug- 
mentation and GLU-response antagonism. Anticonvulsant barbiturate concentrations 
producing modulation of amino acid responses and direct chloride-mediated inhibit- 
ion were different, consistent with an acceptable therapeutic index between the anti- 
convulsant and anesthetic-sedative actions. For anesthetic barbiturates, however, 
these actions occurred at similar concentrations, consistent with a poor therapeutic 
index for anticonvulsant action. Since the above experiments were performed using 
iontophoresis of drugs and amino acids, two important questions remain. First, are 
the reported differences between anticonvulsant and anesthetic barbiturates a conse- 
quence of different transport numbers for iontophoresis of the barbiturates; and 
second, do these actions occur at clinically meaningful barbiturate concentrations? To 
approach these questions, we have investigated barbiturate actions on mouse spinal 
cord neurons in cell culture by applying barbiturates to the bathing medium or by 
local miniperfusion of individual neurons. Thus a direct comparison could be made 
between barbiturate action and concentration. 
MATERIALS AND METHODS 
Recordings were made from neuronal cell cultures prepared by mechanically 
dissociating spinal cords derived from 12.5-14-day-old mouse embryos; the details of 
this procedure have been described elsewhere 25. A minimum of 5 weeks was allowed 
for maturation of the cultures prior to electrophysiological experiments. Culture 
dishes were placed on the modified stage of an inverted phase-contrast microscope and 
maintained at 35-37 °C. Large diameter (25-50 #m) multipolar spinal cord neurons 
were penetrated under direct vision using either 4 M KAc- or 3 M KCl-filled micro- 
pipettes (25--40 M t~). Simultaneous recording of membrane potential and injected 
current was achieved using a conventional bridge circuit. Data were recorded on a 6- 
channel Brush polygraph (2600). 
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Four different actions of PB and PhB were investigated: (1) changes in post- 
synaptic GABA-responses; (2) anticonvulsant actions on bicuculline (BICUC)-indu- 
ced convulsive activity; (3) alterations in levels of spontaneous activity; and (4) direct 
postsynaptic effects. During electrophysiological recordings, the cultures were bathed 
in Dulbecco's phosphate buffered saline (DPBS) (136.75 mM NaCI, 2.68 mM KCI, 
0.90 mM CaC12, 0.49 mM MgCI2.6 HzO, 8.06 mM Na2HPO4"7H20, 1.47 mM 
KH2POa, 5.56 mM glucose) which maintained pH between 7.2 and 7.4. When changes 
in membrane potential were being recorded (as in 1 and 4 above), MgCIz was added to 
elevate [Mg 2+] to 10 mM and abolish most spontaneous synaptic activity. 
A constant current stimulator was used to iontophoretically apply GABA (0.5 
M, pH 1.32) from high resistance (> 50 M f~) glass micropipettes. The tips of GABA- 
containing pipettes were placed about 2 #m from the cell membrane, and responses to 
GABA were obtained by passing 2.5-9.0 nA current pulses of 100-500 msec. These 
two parameters were adjusted to obtain control GABA-responses of 5-10 mV. 
Because KCl-filled recording micropipettes were used, the chloride equilibrium 
potential was depolarized to about ---20 mV and neuronal responses to GABA were 
depolarizing. Short current pulses were continuously injected through the recording 
micropipette to evaluate the effects of GABA, PB and PhB on membrane conductan- 
ce. 
For acute administration of barbiturates, a pressure-mediated mini-perfusion 
(MP) system was used. The tips of glass micropipettes were broken off, leaving an 
opening 5-10 #m in diameter. The micropipettes were then filled with the appropriate 
concentration of barbiturate, fastened to micromanipulators and attached to sections 
of polyethylene tubing which were connected to a pressure regulator. The duration of 
0.5 to 2.0 psi pressure pulses was varied from 500 msec to 3 sec. The tips of the MP 
pipettes were placed in the region of the tips of GABA iontophoretic pipettes, but 
somewhat further away from the cell (10-15 #m). Thus, GABA was applied iontopho- 
retically prior to and during MP of cells with varying concentrations of PB and PhB. 
Recordings were made using KCl-containing micropipettes and membrane potential 
was hyperpolarized to --60 to --90 mV. 
To measure anticonvulsant action, the culture was first bathed in recording 
medium containing 40/,M BICUC. At this dose, BICUC has been shown to produce 
abnormal bursting or paroxysmal depolarizing events (PDE) in all spinal cord 
neurons T M .  Increasing amounts of barbiturate were added to the medium, and their 
effects on this abnormal activity were recorded with KAc-filled micropipettes. All 
experiments were completed within 2 h of preparation of the BICUC solution since it 
is unstable in solution 10. The same paradigm was used to measure barbiturate-induced 
alteration in spontaneous neuronal activity, except that BICUC was not added to the 
recording medium. 
Barbiturate actions on neuronal membrane properties were studied using MP 
pipettes as described above; however, no iontophoretic pipettes were present. Mem- 
brane potentials were maintained at ---45 to --65 mV, and barbiturates were applied 
to cell surfaces by MP. Changes in membrane potential and conductance were 
recorded using KCl-filled micropipettes, and thus the chloride-dependent barbiturate 
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responses were depolarizing rather than  hyperpolarizing. PB, PhB, 
B ICUC were purchased from Sigma Chemicals. 
G A B A  and  
RESULTS 
Barbiturates abolished BICUC-induced paroxysmal depolarizing events 
Addi t ion  of 40/~M BICUC to the bathing medium produced P D E in 100 ~ of 
neurons  studied (Fig. 1 top;  0 / tM) .  Both PhB and  PB abolished the BICUC-induced  
PDE (Fig. 1 top;  100/~M, 200/~M) in a dose-dependent  manne r  over a barbi turate  
range of  25-500/~M (Fig. 1 bottom). PB had a 5 0 ~  effective dose (EDs0) for suppres- 
sion of PDE at 150/ tM and was slightly more potent  than  PhB whose EDs0 was 170 
/~M. As barbi turate  concentra t ion was increased, neuronal  firing was altered from a 
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Fig. 1. Phil and PB abolished paroxysmal depolarizing events in spinal cord neurons in cell culture. 
When 40 #M BICUC was added to normal bathing medium, 100% of neurons developed PDE. As 
increasing concentrations of barbiturates were added to the bathing medium, PDE was recorded in 
fewer neurons and at 500/~M all neurons displayed normal spontaneous activity. The specimen 
records at the top are polygraph records of intracellular recordings made with 4 M KAc-filled micro- 
pipettes which were obtained in DPBS containing 0, 25, 100 and 200/~M PhB and PB. Action poten- 
tial amplitudes are reduced due to the limited frequency response of the recorder, The records at 0/~M 
barbiturates show typical PDE and those at 200 #M show normal spontaneous activity. Recordings 
were only accepted if resting membrane potential was above 40 mV, evoked action potentials were at 
least 40 mV and the recording was stable and maintained for more than 2 rain. Each point on the 
graph represents from 4 to 16 recordings from single neurons with a total of 23 cells for PB and 42 cells 
for PhB. 
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Fig. 2. PhB and PB augmented postsynaptic GABA-responses. Intracellular recordings were made 
using micropipettes filled with 3 M KCI in bathing medium containing 10 mM Mg ++ to suppress 
spontaneous activity. GABA was applied by iontophoresis (PhB: 4, 5 nA; PB 3, 2.5 nA) for 100 msec 
to achieve responses of 10-15 mV. After control GABA-responses were obtained (CON), the tip of a 
barbiturate-containing miniperfusion pipette was positioned within 25/~m of the tip of the GABA 
iontophoretic pipette. GABA-responses were then obtained while barbiturates were applied by mini- 
perfusion. The specimen records shown at the top were representative of the augmentation of GABA- 
responses produced by 50 and 100/~M PhB and PB. Each point on the plot represents the average 
GABA-response augmentation on 3 to 8 cells (PB 15 and PhB 33) with 2-4 trials per cell. Membrane 
potential was hyperpolarized to --60 to --90 mV to increase the separation between chloride equili- 
brium potential and membrane potential and thus achieve large GABA-responses at low iontophore- 
tic currents. 
fully developed paroxysmal pattern to one o f  periodic bursts or volleys o f  action 
potentials (Fig. 1 top). For  example, at lower barbiturate concentrat ions action 
potentials were often seen on the leading edge o f  the depolarization and/or  the 
amplitude o f  the depolarization was decreased (Fig. 1 top ;  25 and 100/tM). At  higher 
concentrat ions o f  PB or  PhB, the convulsant  action o f  B I C U C  was overcome and the 
cells showed normal  spontaneous activity (Fig. 1 top ;  200 #M).  It should be noted that  
a range o f  responses was seen at intermediate barbiturate concentrations. Thus, at 
barbiturate concentrat ions between 50 and 200 #M,  there was a graded mixture o f  
spontaneous activity f rom fully paroxysmal to completely non-paroxysmal .  
Barbiturates augmented postsynaptie GABA-responses 
Both PhB and PB augmented GABA-responses  (Fig. 2 top) in a dose-dependent 
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fashion (Fig. 2 bottom). Augmentation occurred over barbiturate concentrations of 
25-500/~M. PB (ED50 of 50/~M) was slightly more potent than PhB (ED50 of 75/~M) 
(Fig. 2 bottom). Augmentation was unassociated with alterations in resting membrane 
properties up to 100/~M for PB and 500 # M  for PhB. Above these concentrations, PB 
and PhB directly increased membrane conductance and depolarized membrane 
potential. 
Barbiturates suppressed spontaneous neuronal activity 
Intracellular recordings made from neurons bathed in DPBS revealed normal 
spontaneous activity consisting of random mixtures of  action potentials and excitatory 
and inhibitory synaptic potentials (Fig. 3 top; con). As PB concentration was 
increased, no consistent alterations in spontaneous activity were recorded until the 
concentration was above 100/~M. Above this concentration, spontaneous activity was 
reduced and in some neurons was absent (Fig. 3 top; 500 #M). The incidence of such 
quiescence or silence increased from 0 to 100 % over the 100-500/zM range (Fig. 3 
bottom) with an EDs0 of  280/~M. As PhB concentration was increased, a similar 
progression from normal spontaneous activity to quiescence occurred (Fig. 3 top), but 
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Fig. 3. PhB and PB reduced spontaneous activity. Spontaneous activity was recorded from neurons in 
DPBS medium using 4 M KAc-filled micropipettes and consisted of randomly occurring synaptic and 
action potentials (CON). As barbiturate concentration was increased, spontaneous activity was 
reduced and at higher concentrations suppressed (500/~M, 1 mM). At each concentration, there was a 
dose-dependent increase in the percentage of cells with no spontaneous activity (bottom). In the 
graph, each point represents recordings from 4 to 7 different cells with a total of 22 cells for PB and 18 
cells for PhB. 
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Fig. 4. PhB and PB directly altered membrane potential and conductance, lntracellular recordings 
were made with 3 M KCl-filled micropipettes in DPBS medium containing 10 mM Mg 2+ and barbitu- 
rates were applied by miniperfusion. Membrane potential was hyperpolarized to ---45 to - -65 mV and 
brief (50 msec) hyperpolarizing constant current pulses were applied through the recording micro- 
pipette using the bridge technique. Specimen records (top) show that both barbiturates depolarized 
membrane potential and increased membrane conductance but higher concentrations were required 
for PhB than for PB. In the plot of barbiturate response vs concentrations, each point represents an 
average depolarization obtained from 4 to 14 cells with a total of 36 cells for PB and 35 for PhB. 
the PhB concentration range that produced silence was from 500 to 4000/~M (Fig. 3 
bottom) with an EDs0 of 1300 #M. 
Barbiturates increased neuronal membrane conductance and altered membrane potential 
Barbiturates were applied to spinal cord neurons by MP and intracellular 
recordings were made with 3 M KCl-containing micropipettes. With concentrations 
up to 100 #M, PB application did not alter membrane conductance or potential (Fig. 4 
top; 100/~M). Above 100 #M, however, PB increased membrane conductance and 
depolarized membrane potential in a dose-dependent manner (Fig. 4 top; 100, 200 
#M). Over the range of 100-750/,M, PB application evoked responses up to 20 mV 
(Fig. 4 bottom). Application of 500/aM PhB, however, produced no direct membrane 
response (Fig. 4 top; 500 #M). Above this concentration, PhB evoked similar dose- 
dependent depolarization and increases in membrane conductance (Fig. 4 top; 2,4 
mM). Over the concentration range of 100(0-4000 /~M, PhB directly depolarized 
membrane potential up to 22 mV (Fig. 4 bottom). Thus, while both barbiturates 
directly increased membrane conductance and depolarized neurons, PB was much 
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Fig. 5. Dose-dependency of PhB actions. PhB antagonized BICUC-induced PDE and augmented 
GABA-responses over similar concentrations (25-500/~M), but higher concentrations of PhB were 
required for both abolition of spontaneous activity and depolarization (500-4000/~M). 
more potent than PhB with 10 mV responses being produced at 340 and 2000/tM 
respectively. 
Dose-dependency of  PB and PhB actions was different 
As presented in the previous sections, both PB and PhB antagonized BICUC- 
induced PDE, produced quiescence, augmented postsynaptic GABA-responses and 
directly increased membrane conductance. However, these barbiturate actions did not 
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Fig. 6. Dose-dependency of PB actions. While augmentation of GABA responses and suppression of 
BICUC-induced PDE occurred at lower PB concentrations (25-500 /tM)than abolition of spon- 
taneous activity and depolarization (100-1000/~M), the degree of overlap was considerable (when 
compared with the effects of PhB on these 4 actions). 
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and PB. PhB antagonized BICUC-induced PDE and augmented GABA-responses 
over similar concentration ranges (25-200 #M) (Fig. 5) and also directly altered 
membrane properties and produced quiescence over similar concentrations (500-4000 
/,M) (Fig. 5). PB also antagonized BICUC-induced PDE and augmented GABA- 
responses over the same 25-200/,M range (Fig. 6), but the direct membrane actions 
and production of quiescence occurred together over only a slightly higher concentrat- 
ion range (100-500/,M) (Fig. 6). Thus, augmentation of GABA-responses and anti- 
convulsant action were correlated and were produced over similar concentrations by 
both barbiturates. The direct increase in chloride conductance and quiescence were 
correlated for each barbiturate but occurred at much lower concentrations for PB 
than for PhB. Thus, while both barbiturates had similar actions, there was a difference 
in their dose-dependency. 
DISCUSSION 
PhB and PB had similar actions in these experiments with both barbiturates: (1) 
abolishing convulsant-induced PDE; (2) augmenting postsynaptic GABA-responses; 
(3) abolishing spontaneous activity; and (4) increasing membrane chloride conduc- 
tance directly. What, then, accounts for the anticonvulsant action of both barbitu- 
rates ? 
As a model of barbiturate anticonvulsant action, we studied the dose-depend- 
ency of barbiturate antagonism of BICUC-induced paroxysmal activity. BICUC is a 
convulsant compound and an antagonist of GABA-mediated postsynaptic inhibi- 
tionS,11,15. Intracellular recordings obtained from cortical neurons following topical 
convulsant application have demonstrated abrupt and randomly occurring depolari- 
zations termed paroxysmal depolarizing shifts which appear to be the intracellular 
electrophysiological events underlying interictal spikes recorded in the surface electro- 
encephalogram of patients with epilepsyl,16,2L In neurons in primary dissociated cell 
culture derived from mouse spinal cord, BICUC evoked similar paroxysmal depolari- 
zations (PDE)ll, 15. Furthermore, BICUC antagonized GABA-mediated postsynaptic 
responses T M  and displaced [3H] GABA from GABA-binding sites 31. Thus, in spinal 
cord neurons in cell culture, BICUC is a GABA antagonist and produces paroxysmal 
activity. We selected a high BICUC concentration (40 #M) which produced PDE in 
100 ~ of neurons so that in each recording we would have a relatively unambiguous 
endpoint, i.e. presence or absence of PDE. Both PB and PhB abolished BICUC- 
induced PDE over a 25-500/,M range with EDs0s of 150 and 170 #M respectively. PB 
and PhB also augmented GABA-responses over similar concentrations (25-200/,M) 
with EDs0s of 50 and 75/,M respectively. During clinical use of PhB, serum levels of 
10-40/zg/ml (43-172/,M) are generally considered to be in the therapeutic range. 
Since in plasma PhB is about 50 ~ protein bound 10, free-serum levels should be 5-20 
/zg/ml (21.5-86 #M), and in steady-state, this should equilibrate with the central 
nervous system (CNS) and cerebrospinal fluid. Variations in protein binding in differ- 
ent patients could alter these concentrations somewhat, but nonetheless, CNS concen- 
trations of 20-100/~M cover most of the therapeutic range for PhB. The somewhat 
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increased range of PhB concentration needed to achieve 100 % suppression of PDE 
was probably a consequence of the high BICUC concentration that we selected. PB 
had anticonvulsant activity over a similar range of concentrations but was slightly 
more potent, consistent with the known anticonvulsant activity of PB. Thus, PhB and 
PB antagonized BICUC-induced PDE and augmented GABA-responses over concen- 
tration ranges which were in the therapeutic range for PhB anticonvulsant action. In 
addition, both barbiturates antagonized GLU-responses at the same concentrations 
that augmented GABA-responses13,14. PhB and PB were equally effective in this in 
vitro model of anticonvulsant action and thus their anticonvulsant properties may be 
due at least in part to augmentation of GABA-mediated postsynaptic inhibition. 
What, then, underlies barbiturate anesthetic action? PB and other anesthetic 
barbiturates produce dose-dependent alterations in electroencephalographic (EEG) 
recordings during the development of increasing stages of anesthesia 4. The normal 
EEG is replaced by synchronous, high amplitude, slow (delta) waves during initial 
stages of anesthesia. As surgical anesthesia is achieved, the amplitude of the EEG 
decreases and a suppression pattern develops in which silent low amplitude periods are 
interrupted by bursts of slow wave activity. If anesthetic concentration is further in- 
creased a silent flat EEG ensues. Based on the characteristic finding of a flat EEG with 
deep barbiturate surgical anesthesia or overdose, we used quiescence or silence in 
neuronal activity as an in vitro analog of the deep anesthetic state. It is likely that 
barbiturate concentrations which produced total quiescence were in excess of those 
required to produce surgical anesthesia and thus our assessment of anesthetic action 
tended to bias the dose-response curve for anesthesia to somewhat higher barbiturate 
concentrations. Both PB and PhB decreased spontaneous activity and increased the 
percentage of neurons with no spontaneous activity. However, these two barbiturates 
were not equipotent. PB produced quiescence over the 100-500 #M range while PhB 
required concentrations of 500--4000 #M. PB and PhB also increased membrane 
conductance with a similar difference in potency with PB active from 100 to 750/zM 
(10 mV responses at 340/~M) and PhB active from 1000 to 4000 #M (10 mV responses 
at 2000 /~M). For PB, surgical anesthesia is produced at concentrations (200-300 
#M 26) which overlap the midportion of the PB quiescence dose-response curve. Thus, 
it would appear that clinically relevant concentrations of PB are associated with an in 
vitro correlate of anesthesia, suggesting that the model chosen may be relevant for 
study of anesthetic actions. For PhB, however, very high concentrations were required 
to produce quiescence. This is consistent with the clinical observation that large doses 
of PhB can be administered to patients in status epilepticus without inducing 
anesthesia. This anesthetic action was correlated with the direct action of PB on 
membrane chloride conductance. For PhB, a similar correlation was present between 
quiescence and direct GABA mimetic action but at much higher concentrations. These 
findings suggest that barbiturate anesthesia may be produced, at least in part, by a 
direct PB action to increase chloride conductance and thus hyperpolarize neurons and 
reduce activity:The difference between the clinical actions of PhB and PB may be due 
to the different dose-dependency of these actions. For PhB, anticonvulsant action and 
GABA-augmentation were produced at low concentrations (25-200 /~M) while 
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anesthetic action and direct increase in chloride conductance occurred at high 
concentrations (500-4000/~M). Thus the therapeutic index for anticonvulsant action 
with PhB would be excellent, with a large dose separation between anticonvulsant 
effects and anesthetic-sedative actions. For  PB, anticonvulsant and anesthetic-sedative 
actions would occur at comparable concentrations, and thus while PB would have 
both actions, its therapeutic index for anticonvulsant action would be poor. Therefore, 
PB would be useful as an anticonvulsant only if needed for status epilepticus and if 
concurrent anesthesia was acceptable. Consistent with this interpretation was the 
finding that both PhB and PB produced dose-dependent anticonvulsant actions in 
mice against pentylenetetrazol-induced and maximal electroshock seizures and that 
both barbiturates exerted dose-dependent neurotoxic effects as measured using a 
rotorod technique 23. However, the 'protective index' (PI: ratio of neurotoxic to 
anticonvulsant EDs0s) was different for each barbiturate with PB having a poor  P1 of 
0.79-0.98 and PhB a large PI of  2.71-3.41. This is similar to our finding of an 
anesthetic to anticonvulsant EDs0 ratio of  1.9 for PB and 7.2 for PhB. 
Barbiturates also have presynaptic actions to decrease calcium-accumulation by 
cortical synaptosomesa,7, zl and to block calcium-dependent release of GABA, gluta- 
mate and acetylcholine6, 9. However, PB decreased calcium accumulation only at 
concentrations of  at least 300 #MT. Release of  GABA from cortical synaptosomes was 
not reduced by 100/~M PB 20 but was decreased by 200/zM to 1 mM PB 6,a. Thus, 
barbiturates decreased presynaptic calcium entry and reduced neurotransmitter 
release at concentrations that were anesthetic but not anticonvulsant. This suggests 
that barbiturate anesthesia may be a consequence of a presynaptic action of 
barbiturates to reduce transmitter release as well as of  postsynaptic actions to increase 
GABA-mediated inhibition, to decrease GLU-mediated excitation and to directly 
increase chloride conductance. 
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